ReviewCancers2023
Frequency of Germline and Somatic
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial.Journal for immunotherapy of cancer · 2026Trial
- Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan.International journal of clinical oncology · 2026Review
- Factors Affecting Quality Control (QC) Failure Rates in Somatic Breast Cancer (BRCA) Gene Testing in Castrate Resistant Prostate Cancer: Experiences From an Australian Cancer Care Centre.Asia-Pacific journal of clinical oncology · 2026Article
- Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies.International journal of molecular sciences · 2026Review
- BRCA Testing in Prostate Cancer: A Histopathologist's Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.Future oncology (London, England) · 2026Review
- Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy.Cancer science · 2026Article
- Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions.Current opinion in oncology · 2026Review
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- Article
- Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?Current oncology (Toronto, Ont.) · 2025Review
- Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.The oncologist · 2025Observational
- BRCA Mutation Testing in Men With Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice.Asia-Pacific journal of clinical oncology · 2025Review
- Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.Cancer medicine · 2025Article
- Storage Time and DNA Quality DetermineCancers · 2025Article
- Review
- Article
- Article
- UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results.BMJ oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In prostate cancer (PC), the presence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.